News Sentiment

AVTX sentiment intelligence

Avalo Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 55 Balanced news tone 56 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 19.21 Week of 10 Jul 2026
Weighted tone 55/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

79/100 classification confidence.

Company focus 47

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend active

+2.0% over one week, +30.1% over four weeks, trend active, and materially above fair value.

Latest direct headline Positive

(AVTX) as a Liquidity Pulse for Institutional Tactics

Market Reaction

Balanced read

64/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 79/100 classification
One-week reaction 2.0% Price confirming higher
Trend fit Trend active 30.1% over four weeks
Fair value 42.2% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 14
Neutral 39
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 47
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 19
Market source 8
TradingView 5
GlobeNewswire 5
simplywall.st 4
GuruFocus 2
Finviz 2
StockStory 1

Event Lens

What the news is about

Classified themes
Market update 29
Earnings 15
Analyst action 5
Balance sheet 4
Deals and strategy 2
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 56
Stock Traders Daily Direct company coverage

(AVTX) as a Liquidity Pulse for Institutional Tactics

This article analyzes Avalo Therapeutics Inc. (NASDAQ: AVTX), noting weak near-term sentiment but strong mid- and long-term outlooks. It identifies a significant 89.4:1 risk-reward setup, targeting a 24.6% gain, and provides three AI-generated trading strategies: Position Trading

Tone
Positive 71/100
Event
Balance sheet
Published
15 Jul 2026 01:47
Source
Stock Traders Daily
Investing.com South Africa Direct company coverage

Leerink initiates Avalo Therapeutics stock with outperform rating By Investing.com

Leerink has initiated coverage on Avalo Therapeutics Inc. (NASDAQ:AVTX) with an Outperform rating and a $38.00 price target. The biotechnology company, specializing in IL-1β-based therapies, is advancing its lead program, abdakibart, towards a Phase 3 trial and plans to file an I

Tone
Positive 76/100
Event
Analyst action
Published
07 Jul 2026 12:10
Source
Investing.com South Africa
The Manila Times Direct company coverage

Avalo Therapeutics to Participate in the Leerink Partners Therapeutics Forum

Avalo Therapeutics, a clinical-stage biotechnology company, announced that its management will host one-on-one investor meetings at the Leerink Partners Therapeutics Forum on July 15, 2026, in Boston. The company focuses on developing therapeutics targeting the IL-1β pathway for

Tone
Positive 66/100
Event
Market update
Published
07 Jul 2026 11:01
Source
The Manila Times
Stock Titan Direct company coverage

Avalo Therapeutics sets one-on-one investor meetings at Leerink Forum

Avalo Therapeutics (Nasdaq: AVTX) announced it will participate in the Leerink Partners Therapeutics Forum on July 15, 2026, in Boston. Management plans to host one-on-one investor meetings to discuss the company's focus on developing therapeutics targeting the IL-1β pathway for

Tone
Positive 77/100
Event
Market update
Published
07 Jul 2026 11:00
Source
Stock Titan
Investing.com Direct company coverage

Leerink initiates Avalo Therapeutics stock with outperform rating

Leerink initiated coverage on Avalo Therapeutics Inc. (NASDAQ:AVTX) with an Outperform rating and a $38.00 price target, noting the company's lead drug abdakibart has shown positive Phase 2 data for hidradenitis suppurativa. Avalo Therapeutics, a clinical-stage biotechnology comp

Tone
Positive 74/100
Event
Analyst action
Published
06 Jul 2026 23:41
Source
Investing.com
Stock Titan Direct company coverage

Millennium Group (AVTX) reports shared control of 9,857 Avalo shares (Jul 2026)

Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have filed an amended passive investment disclosure (SCHEDULE 13G/A) for Avalo Therapeutics, Inc. They report shared voting and shared dispositive power over 9,857 shares of Avalo common stock, re

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 21:10
Source
Stock Titan
GuruFocus Direct company coverage

AVTX Initiates Coverage by Leerink Partners -- Rating Set to Outperform

Leerink Partners has initiated coverage on Avalo Therapeutics (AVTX) with an "Outperform" rating and a price target of $38.00. Despite this positive analyst outlook, GuruFocus indicates AVTX is significantly overvalued at $18.86 with a GF Value™ of $0.03, showing a 62,783.3% over

Tone
Negative 28/100
Event
Analyst action
Published
06 Jul 2026 14:10
Source
GuruFocus
Stock Titan Direct company coverage

Avalo Therapeutics (AVTX) director receives fully vested options grant

Avalo Therapeutics director Philip Ron M was granted 69 fully vested stock options on June 30, 2026, as compensation. Each option has an exercise price of $18.48 and a grant date fair value of $15.04, with an expiration date of June 30, 2036. This transaction was reported in an S

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 19:39
Source
Stock Titan
Stock Titan Direct company coverage

Avalo Therapeutics (AVTX) CMO exercises options, sells 4,654 pre-planned shares

Avalo Therapeutics Chief Medical Officer Mittie Doyle executed a pre-planned exercise-and-sell transaction. On June 30, 2026, Doyle sold 4,654 shares of AVTX common stock at $20.00 per share, while simultaneously exercising options to acquire the same number of shares at strike p

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 19:39
Source
Stock Titan
Stock Titan Direct company coverage

Avalo Therapeutics (AVTX) director granted fully vested options on 1,080 shares

Avalo Therapeutics director Rita Jain was granted fully vested stock options for 1,080 shares of AVTX common stock on June 30, 2026. The options have an exercise price of $18.48 per share and will expire on June 30, 2036. This transaction increased her direct holdings to options

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 19:39
Source
Stock Titan
Stock Titan Direct company coverage

Avalo Therapeutics (AVTX) director receives grant of 1,105 stock options

Avalo Therapeutics director Kevin Robert Lind was granted 1,105 stock options on June 30, 2026. These options, exercisable at $18.48 per share, are fully vested at grant and expire on June 30, 2036. This transaction leaves him with 1,105 options outstanding.

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 19:39
Source
Stock Titan
Finviz Direct company coverage

AVTX - Avalo Therapeutics Inc Volatility & Greeks

This article provides a detailed financial overview of Avalo Therapeutics Inc (AVTX), including its last closing price, key financial metrics, volatility, and various performance indicators. It covers market capitalization, income, sales, earnings per share, insider and instituti

Tone
Negative 39/100
Event
Earnings
Published
01 Jul 2026 09:11
Source
Finviz
TradingView Direct company coverage

Price to earnings forward of Avalo Therapeutics, Inc. – NASDAQ:AVTX

This article displays financial data for Avalo Therapeutics, Inc. (NASDAQ: AVTX), specifically its forward price-to-earnings ratio. It indicates that the market was closed with no trades at the time of publication, and provides copyright and data source information for the financ

Tone
Neutral 50/100
Event
Earnings
Published
01 Jul 2026 08:08
Source
TradingView
TradingView Direct company coverage

Avalo Therapeutics Inc Actuals & Estimates (NASDAQ:AVTX)

This article provides an overview of Avalo Therapeutics Inc. (NASDAQ: AVTX), including its current stock price, market capitalization, financial performance, and analyst forecasts. It details the company's recent stock performance, earnings, revenue, and upcoming earnings report

Tone
Neutral 50/100
Event
Earnings
Published
30 Jun 2026 21:09
Source
TradingView
Finviz Direct company coverage

AVTX - Avalo Therapeutics Inc Latest SEC Filings

This article provides key financial data and performance metrics for Avalo Therapeutics Inc. (AVTX). It includes details on market capitalization, income, sales, EPS, insider ownership, institutional ownership, and various profitability ratios, alongside recent stock performance

Tone
Neutral 50/100
Event
Earnings
Published
30 Jun 2026 09:08
Source
Finviz
TradingView Direct company coverage

Price to sales forward of Avalo Therapeutics, Inc. – NASDAQ:AVTX

This article provides the "Price to sales forward" metric for Avalo Therapeutics, Inc. (NASDAQ:AVTX). It is a financial data point displayed within the context of a TradingView page for the company. The specific value of the metric is not visible in the provided text, but the cat

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 05:41
Source
TradingView
www.marketscreener.com Direct company coverage

Avalo Therapeutics, Inc.(NasdaqCM: AVTX) added to Russell 3000E Growth Benchmark

Avalo Therapeutics, Inc. (NasdaqCM: AVTX) has been added to the Russell 3000E Growth Benchmark. The clinical-stage biotechnology company focuses on immune dysregulation treatments, with lead asset AVTX-009 targeting inflammatory diseases. Analyst consensus on the stock is "BUY" w

Tone
Positive 77/100
Event
Analyst action
Published
29 Jun 2026 04:10
Source
www.marketscreener.com
The Globe and Mail Direct company coverage

Avalo Therapeutics Appoints Ron Philip to Board of Directors

Avalo Therapeutics, a clinical-stage biotechnology company, announced the appointment of Ron Philip to its Board of Directors. Mr. Philip brings over 30 years of biopharmaceutical leadership and commercial expertise, which will be invaluable as Avalo advances its lead asset, abda

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 00:39
Source
The Globe and Mail
marketscreener.com Direct company coverage

Avalo Therapeutics to Join Russell 2000, Russell 3000 Indexes

Avalo Therapeutics, Inc. is set to be included in the Russell 2000 and Russell 3000 Indexes, a move that could increase its visibility and liquidity among investors. The company, a clinical-stage biotechnology firm, focuses on treatments for immune dysregulation with lead asset A

Tone
Positive 72/100
Event
Balance sheet
Published
26 Jun 2026 11:40
Source
marketscreener.com
GuruFocus Direct company coverage

Avalo Therapeutics (AVTX) Joins Russell 2000 and 3000 Indices

Avalo Therapeutics Inc (AVTX) has been included in both the Russell 2000 and Russell 3000 Indices, a move that could enhance visibility and liquidity. Despite this milestone and a recent public offering, the company faces significant challenges highlighted by a low GF Score of 23

Tone
Neutral 50/100
Event
Balance sheet
Published
26 Jun 2026 11:40
Source
GuruFocus
GlobeNewswire Direct company coverage

Avalo Therapeutics to Join the Russell 2000® and Russell 3000® Indexes

Avalo Therapeutics (Nasdaq: AVTX) announced its inclusion in the small-cap Russell 2000® Index and the broad-market Russell 3000® Index, effective after the U.S. equity markets close on June 26, 2026. These indexes are widely used benchmarks by investment managers. The company is

Tone
Positive 74/100
Event
Market update
Published
26 Jun 2026 10:40
Source
GlobeNewswire
Stock Titan Direct company coverage

Avalo Therapeutics (AVTX) CMO trades 1,450 shares in 10b5-1 exercise-and-sell

Avalo Therapeutics' Chief Medical Officer, Doyle Mittie, executed an exercise-and-sell transaction involving 1,450 shares of company stock. Mittie exercised options at $8.04 per share and simultaneously sold the same number of shares at $18.00 per share. These transactions were m

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 08:41
Source
Stock Titan
Stock Titan Direct company coverage

Avalo Therapeutics (AVTX) director awarded 40,200 stock options at $17.83 strike

Avalo Therapeutics director Philip Ron was granted 40,200 stock options at an exercise price of $17.83 per share. These options, which vest in three annual installments and expire on June 23, 2036, are a common form of equity compensation aimed at aligning board members' interest

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 07:40
Source
Stock Titan
Investing.com Nigeria Direct company coverage

Form 4 Avalo Therapeutics Inc For: 25 June By Investing.com

This article from Investing.com reports on a Form 4 filing for Avalo Therapeutics Inc. dated June 25, 2026. Form 4s disclose transactions made by company insiders. The article provides the ticker symbol AVTX, which showed a 1.11% price change, and links to relevant financial mark

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 07:40
Source
Investing.com Nigeria